WHO Clinical Classification of PH Complex Cases in PH.

Slides:



Advertisements
Similar presentations
Upfront Combination Therapy vs Step-Up Approach for PAH:
Advertisements

Exploring Early Combination Therapy in PAH
Monitoring and Modifying Treatment in PAH
NOACs for Cancer-Associated Thrombosis:
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Acute Heart Failure.
A Paradigm Shift in PAH.
An Update on Oral Prostanoids: Advancing Care for PAH?
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
The Clinical Enigma of Cardiogenic Shock
Setting the Stage – PAH Therapy Trials Current PAH Pharmacotherapies.
UNDERSTANDING RISK STRATIFICATION IN PAH:
The Latest Data on Oral Prostacyclin Therapy in PAH
New Treatments for CTEPH
All About PAH:.
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
GLP-1 Receptor Agonists: How Early Is Appropriate?
Decision-making in the eRA of Treating to Target
PAH Therapy Revisited.
PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence
Improving Risk Assessment and Early Diagnosis in PAH
Updates in Pulmonary Arterial Hypertension
Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy
Tuberous Sclerosis Complex Fundamental Concepts in Diagnosis and Management.
Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Evolving Science of PAH Treatment
Risk Assessment in PAH.
2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.
Examining the Latest Evidence in PAH
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Current and Emerging Data in CTEPH
Case Study 56-year-old Presents With 1 Year of Worsening Dyspnea
Oral Prostanoids and PAH
Navigating Treatment Options in PAH
Preventing Clinical Events in PAH
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
PAH and Prostacyclin Pathways in Focus
When Is Intrathecal Drug Delivery Appropriate?
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
PAH-Related Morbidity as a Predictor of Mortality
PAH Treatment.
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Pulmonary Arterial Hypertension and Connective Tissue Disease
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.
What's New in PAH?.
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Oral Prostacyclin Pathway Agents in PAH
The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.
Group 1 PAH: Current Therapies
Incorporating Prostacyclins Into Practice
Improving Adherence to Antiplatelet Therapy After an ACS Event
Perspective on the Multidisciplinary Management of PAH
Patient Stories in PAH: Sequential Therapy in a FC II Patient
Optimal Treatment of PAH
When Is Intrathecal Drug Delivery Appropriate?
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Prostacyclin Pathway Agents in Action
Transitioning Therapy in PAH: Practical Strategies and Considerations
Incorporating New PAH Treatments Into Clinical Practice
PAH Pathways: What Do the Data Tell Us?”
Binge Eating Disorder.
Clinical Comparisons in CTEPH
Pulmonary Arterial Hypertension and Hospitalizations
Importance of Early Diagnosis and Management in SMA
What's New in PAH?.
My PAH Patient.
Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure
Presentation transcript:

WHO Clinical Classification of PH

Complex Cases in PH

Diagnostic Approach to PH

Care Coordination in PH

Current Trends in PAH Prognosis and Treatment

Emerging Trends in PAH Therapy

Panelist

Goals of Therapy in PAH

Novel Therapies in PAH Riociguat

Riociguat Trials

Fixed End Point vs Event-driven Trials

Event-driven Trials (cont) SERAPHIN

Event-driven Trials (cont) GRIPHON

Event-driven Trials (cont) AMBITIONa,b

Upfront Combination vs Add-on Therapy?

The Future of Oral Prostacyclins in PAH

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)